SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Järnum Sofia) "

Sökning: WFRF:(Järnum Sofia)

  • Resultat 1-10 av 13
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Engström, Katarina, 1956, et al. (författare)
  • The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
  • 2006
  • Ingår i: The American journal of pathology. - : Elsevier BV. - 0002-9440 .- 1525-2191. ; 168:5, s. 1642-53
  • Tidskriftsartikel (refereegranskat)abstract
    • Myxoid/round cell liposarcoma (MLS/RCLS) is the most common subtype of liposarcoma. Most MLS/RCLS carry a t(12;16) translocation, resulting in a FUS-DDIT3 fusion gene. We investigated the role of the FUS-DDIT3 fusion in the development of MLS/RCLS in FUS-DDIT3- and DDIT3-transfected human HT1080 sarcoma cells. Cells expressing FUS-DDIT3 and DDIT3 grew as liposarcomas in severe combined immunodeficient mice and exhibited a capillary network morphology that was similar to networks of MLS/RCLS. Microarray-based comparison of HT1080, the transfected cells, and an MLS/RCLS-derived cell line showed that the FUS-DDIT3- and DDIT3-transfected variants shifted toward an MLS/RCLS-like expression pattern. DDIT3-transfected cells responded in vitro to adipogenic factors by accumulation of fat and transformation to a lipoblast-like morphology. In conclusion, because the fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype when expressed in a primitive sarcoma cell line, MLS/RCLS may develop from cell types other than preadipocytes. This may explain the preferential occurrence of MLS/RCLS in nonadipose tissues. In addition, development of lipoblasts and the typical MLS/RCLS capillary network could be an effect of the DDIT3 transcription factor partner of the fusion oncogene.
  •  
2.
  • Jordan, Stanley C, et al. (författare)
  • IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.
  • 2017
  • Ingår i: New England Journal of Medicine. - : Massachusetts Medical Society. - 0028-4793 .- 1533-4406. ; 377:5, s. 442-453
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Donor-specific antibodies create an immunologic barrier to transplantation. Current therapies to modify donor-specific antibodies are limited and ineffective in the most highly HLA-sensitized patients. The IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves human IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor.METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound.RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred.CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
  •  
3.
  • Järnum, Sofia, et al. (författare)
  • LEPREL1, a novel ER and Golgi resident member of the Leprecan family.
  • 2004
  • Ingår i: Biochemical and biophysical research communications. - : Elsevier BV. - 0006-291X .- 1090-2104. ; 317:2, s. 342-51
  • Tidskriftsartikel (refereegranskat)abstract
    • We have identified a novel protein, Leprecan-like 1 (LEPREL1), with profound similarity to the Leprecan family of proteoglycans. The genomic organization of the Leprecan gene family was found to be highly conserved. Expression analysis shows that LEPREL1 is expressed in most tissues as a 3.4 kb transcript encoding an 80 kDa protein. A LEPREL1 specific antibody stains many cell types including adipocytes and neuroendocrine cells of the gastrointestinal epithelium. Muscle tissue contains a specific 6.5 kb transcript and a 200 kDa protein. The 3.4 kb LEPREL1 transcript encodes a 708 amino acid protein containing a signal sequence, four tetratricopeptide repeats (TPRs), a leucine zipper, a P-loop, a prolyl 4-hydroxylase alpha domain (P4Halpha), and a C-terminal KDEL ER-retention motif. LEPREL1 is localized to the ER and Golgi network and over-expressing it affects normal protein disulfide isomerase staining patterns in the ER.
  •  
4.
  • Järnum, Sofia (författare)
  • Molecular studies of genetic changes in myxoid and round cell liposarcoma
  • 2002
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Chromosomal translocations commonly result in the production of fusion genes and the fusion genes are often tumor-type specific. In myxoid and round cell liposarcomas (MLS/RCLS), almost 95% of the cases carry a t(12;16)(q13;p11). In the remaining 5% of the MLS/RCLS tumors, another translocation and fusion gene can be found, i.e. the t(12;22)(q13;q12). These translocations fuse CHOP on chromosome 12 to either TLS on chromosome 16 or EWSR1 on chromosome 22. The result is a TLS-CHOP or EWS-CHOP fusion protein that is believed to be a key player in the development of MLS/RCLS. Normally, CHOP plays a fundamental role in adipogenesis by forming heterodimers with members of the C/EBP family of transcription factors. TLS-CHOP is capable of dimerizing with the same proteins as CHOP, but the outcome is radically different. This thesis focuses on TLS-CHOP and the hypothesis that TLS-CHOP may function as an aberrant transcription factor. As such TLS-CHOP is believed to regulate the expression of a cascade of downstream genes that contribute to the phenotype and malignancy of MLS/RCLS. We have found that the TLS-CHOP fusion protein localizes to distinct nuclear structures which differs largely from the normal TLS and CHOP patterns. The nuclear structures do not overlap with PML nuclear bodies and furthermore, PML nuclear bodies are dislocated in TLS-CHOP-expressing cells. The abnormal localization of the PML tumor suppressor may be an important part of the transforming process in these tumors. Using a subtraction hybridization technique, we have found that several genes are aberrantly expressed in MLS/RCLS compared to normal adipose tissue and may have a function in the development of these tumors. This work resulted in the identification of a novel gene which seems to be associated with a low degree of differentiation. At present the normal function of this protein, LEPREL1, is not known. However, its different domains and intracellular distribution points in the direction that this protein functions as an enzyme in the ER and Golgi pathway. One of the genes identified as over-expressed in MLS/RCLS was the RET proto-oncogene. Further studies showed that the tumor cells produce the activating ligand persephin and that the receptor is phosphorylated. This indicates that it is activated and capable of signaling proliferation and anti-apoptosis into the cell nucleus. Thus, there seems to be an autocrine growth stimulatory loop running in MLS/RCLS tumors and disrupting the RET signaling pathway may be an attractive target for therapy in MLS/RCLS.
  •  
5.
  • Karlsson, Christofer A.Q., et al. (författare)
  • Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS
  • 2018
  • Ingår i: Molecular and Cellular Proteomics. - 1535-9476. ; 17:6, s. 1097-1111
  • Tidskriftsartikel (refereegranskat)abstract
    • Infectious diseases are characterized by a complex interplay between host and pathogen, but how these interactions impact the host proteome is unclear. Here we applied a combined mass spectrometry-based proteomics strategy to investigate how the human proteome is transiently modified by the pathogen Streptococcus pyogenes, with a particular focus on bacterial cleavage of IgG in vivo. In invasive diseases, S. pyogenes evokes a massive host response in blood, whereas superficial diseases are characterized by a local leakage of several blood plasma proteins at the site of infection including IgG. S. pyogenes produces IdeS, a protease cleaving IgG in the lower hinge region and we find highly effective IdeS-cleavage of IgG in samples from local IgG poor microenvironments. The results show that IdeS contributes to the adaptation of S. pyogenes to its normal ecological niches. Additionally, the work identifies novel clinical opportunities for in vivo pathogen detection.
  •  
6.
  •  
7.
  • Krona, Annika, 1973, et al. (författare)
  • Oncostatin M signaling in human glioma cell lines.
  • 2005
  • Ingår i: Oncology reports. - 1021-335X .- 1791-2431. ; 13:5, s. 807-11
  • Tidskriftsartikel (refereegranskat)abstract
    • We have recently found that oncostatin M (OSM) is overexpressed in most human brain tumors. The effects of OSM are unclear with conflicting reports of growth stimulatory or inhibitory effects in various cell types. The aim of this study was to investigate the effects of OSM in 5 glioma cell lines and 7 short-term cultures of human gliomas and in normal cultured human astrocytes. None of the cell lines and short-term cultured tumor cells expressed OSM in vitro. OSM signals through a gp130 containing receptor complex over the JAK/STAT pathway. Immunofluorescence and RT-PCR analysis showed that the tumor cells express gp130 and the other receptor components, LIFRbeta and OSMRbeta. OSM treatment induced phosphorylation of STAT3 and STAT1 indicating presence of a functional JAK/STAT pathway. No OSM effect on proliferation was observed. OSM gave no protective effects against tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced cytotoxicity.
  •  
8.
  • Lorant, Tomas, 1975-, et al. (författare)
  • Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
  • 2018
  • Ingår i: American Journal of Transplantation. - : Elsevier BV. - 1600-6135 .- 1600-6143. ; 18:11, s. 2752-2762
  • Tidskriftsartikel (refereegranskat)abstract
    • Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG-degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single-center, open-label ascending-dose study in highly sensitized patients with chronic kidney disease. Eight patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2 intravenous infusions of IdeS on consecutive days (0.12 mg/kg body weight ×2 [n = 3]; 0.25 mg/kg ×1 [n = 3], or 0.25 mg/kg ×2 [n = 2]). IgG degradation was observed in all subjects after IdeS treatment, with <1% plasma IgG remaining within 48 hours and remaining low up to 7 days. Mean fluorescence intensity values of HLA class I and II reactivity were substantially reduced in all patients, and C1q binding to anti-HLA was abolished. IdeS also cleaved the IgG-type B cell receptor on CD19+ memory B cells. Anti-IdeS antibodies developed 1 week after treatment, peaking at 2 weeks. A few hours after the second IdeS infusion, 1 patient received a deceased donor kidney offer. At enrollment, the patient had a positive serum crossmatch (HLA-B7), detected by complement-dependent cytotoxicity, flow cytometry, and multiplex bead assays. After IdeS infusion (0.12 mg/kg ×2) and when the HLA-incompatible donor (HLA-B7+) kidney was offered, the HLA antibody profile was negative. The kidney was transplanted successfully.
  •  
9.
  • Safavi, Setareh, et al. (författare)
  • HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
  • 2016
  • Ingår i: OncoTarget. - : Impact Journals, LLC. - 1949-2553. ; 7:1, s. 433-445
  • Tidskriftsartikel (refereegranskat)abstract
    • Myxoid sarcoma (MLS) is one of the most common types of malignant soft tissue tumors. MLS is characterized by the FUS-DDIT3 or EWSR1-DDIT3 fusion oncogenes that encode abnormal transcription factors. The receptor tyrosine kinase (RTK) encoding RET was previously identified as a putative downstream target gene to FUS-DDIT3 and here we show that cultured MLS cells expressed phosphorylated RET together with its ligand Persephin. Treatment with RET specific kinase inhibitor Vandetanib failed to reduce RET phosphorylation and inhibit cell growth, suggesting that other RTKs may phosphorylate RET. A screening pointed out EGFR and ERBB3 as the strongest expressed phosphorylated RTKs in MLS cells. We show that ERBB3 formed nuclear and cytoplasmic complexes with RET and both RTKs were previously reported to form complexes with EGFR. The formation of RTK hetero complexes could explain the observed Vandetanib resistence in MLS. EGFR and ERBB3 are clients of HSP90 that help complex formation and RTK activation. Treatment of cultured MLS cells with HSP90 inhibitor 17-DMAG, caused loss of RET and ERBB3 phosphorylation and lead to rapid cell death. Treatment of MLS xenograft carrying Nude mice resulted in massive necrosis, rupture of capillaries and hemorrhages in tumor tissues. We conclude that complex formation between RET and other RTKs may cause RTK inhibitor resistance. HSP90 inhibitors can overcome this resistance and are thus promising drugs for treatment of MLS/RCLS.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 13
Typ av publikation
tidskriftsartikel (11)
konferensbidrag (1)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (12)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Kjellman, Christian (7)
Åman, Pierre, 1953 (4)
Winstedt, Lena (4)
Salford, Leif (3)
Honeth, Gabriella (3)
Björck, Lars (3)
visa fler...
Widegren, Bengt (3)
Darabi, Anna (3)
Larsson, Erik (2)
Bockermann, Robert (2)
Bengtsson, Mats (2)
Tufveson, Gunnar (2)
Bäckman, Lars (2)
Olsson, Andreas (2)
Lindvall, Magnus (2)
Lorant, Tomas, 1975- (2)
Hansson, Magnus (1)
Warnhammar Finnborg, ... (1)
Eriksson, Mikael (1)
Stenman, Göran, 1953 (1)
Malmqvist, Ulf (1)
Skagerberg, Gunnar (1)
Ståhlberg, Anders, 1 ... (1)
Persson, Bertil R (1)
Siesjö, Peter (1)
Malmström, Johan (1)
Fagman, Henrik, 1975 (1)
Wiberg, Charlotte (1)
Olofsson, Anita, 194 ... (1)
Göransson, Melker, 1 ... (1)
Andersson, Carola, 1 ... (1)
Wennberg, Lars (1)
Richter, Johan (1)
Linder, Adam (1)
Kannisto, Päivi (1)
Visse, Edward (1)
Sjögren, Hans Olov (1)
Myklebost, O (1)
Wood, Kathryn (1)
Mandahl, Nils (1)
Baureus Koch, Catrin (1)
Bengtsson, Therese (1)
Olsson, Marita, 1965 (1)
Jonasson, Emma, 1987 (1)
Lundgren, Torbjörn (1)
Eriksson, Britt-Mari ... (1)
Vannas, Christoffer (1)
Eich, Torsten, 1972- (1)
Rydelius, Anna (1)
Fan, Xiaolong (1)
visa färre...
Lärosäte
Lunds universitet (11)
Göteborgs universitet (4)
Uppsala universitet (3)
Chalmers tekniska högskola (2)
Karolinska Institutet (1)
Språk
Engelska (13)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy